Phase 2 study for people with Chronic Kidney Disease

By invitation Phase 2

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status By invitation
Phase Phase 2
Sponsor Eledon Pharmaceuticals
Registry number NCT06126380
Started 25 October 2023 Today 16 October 2026 Estimated completion 1 December 2029

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Royal Adelaide Hospital Adelaide SA Status not stated
Fiona Stanley Hospital Perth WA Status not stated

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years to 100 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 132

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Successfully completed qualifying Parent study, where entry into the OLE was offered;

* Continue to be able to understand the key components of the study as described in the written ICF, and is willing and able to provide written informed consent;

* Agree not to participate in another interventional study while on treatment;

* If female, is surgically sterile or 2 years postmenopausal. Women of childbearing potential may be enrolled if a pregnancy test is negative at baseline. Women of childbearing potential and men with partners that are of childbearing potential must agree to use highly effective methods of contraception from baseline, through 90 days after the last administration of the study drug. Examples of acceptable methods of contraception are described in Table 6.

* If male, agree to use a medically accepted highly effective method of contraception and agree to use this method for 90 days after last administration of the study drug and agree to not donate sperm for 90 days after last administration of the study drug.

Exclusion Criteria:

* Unwilling or unlikely to comply with the study requirements, in the opinion of the Investigator;

* Met any of the stopping criteria or discontinued study drug in the Parent study;

* Pregnant or breastfeeding.

Dates on the record

Started 25 October 2023
Estimated completion 1 December 2029
Registry last updated 10 December 2025
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 10 December 2025.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.